Socioeconomic inequalities in health-related quality of life during the COVID-19 pandemic: a six-country comparison using the EQ-5D-5 L.

Publication date: Jun 08, 2026

Despite the growing attention to health inequalities, there is no global consensus on how to measure socio-economic status. This study examined inequalities in health-related quality of life (HRQoL) during the early phase of the COVID-19 pandemic across six countries-China, Italy, the Netherlands, Sweden, the United Kingdom (UK), and the United States (US)-using three SES indicators: education level, income, and work status. Between April and June 2020, individuals aged 18-75 years old completed a web-based survey. HRQoL was measured using the EQ-5D-5L Level Sum Score (LSS), where higher scores indicate poorer health. Country-specific differences in LSS across SES groups were assessed using Kruskal-Wallis and Mann-Whitney U tests. Multiple linear regression models, adjusted for age, gender, and chronic conditions, were used to explore associations between SES indicators and HRQoL. No formal correction for multiple testing was applied. Data from 17,607 respondents were analyzed. In all countries except Italy, individuals with lower education levels reported significantly higher LSS scores. The largest disparity was observed in the UK. In the Netherlands, Sweden, the UK, and the US, lower-income groups also had higher LSS scores, while no such differences were observed in China or Italy. Across all countries, unemployed individuals consistently reported worse HRQoL. Regression analyses confirmed that younger age, chronic conditions, and unemployment were strongly associated with poorer HRQoL. Substantial SES-related health inequalities in HRQoL were observed during the COVID-19 pandemic, especially in the UK. Work status emerged as a particularly strong and consistent predictor across countries.

Open Access PDF

Concepts Keywords
Italy COVID-19
June EQ-5D-5L
Pandemic Health inequality
Sweden Socio-economic status

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH LSS
disease MESH chronic conditions
disease MESH eco
drug DRUGBANK Cysteamine
drug DRUGBANK Flunarizine
disease MESH infection
drug DRUGBANK Trestolone
drug DRUGBANK Amlodipine
disease MESH included
disease MESH fac
disease MESH pain
disease MESH anxiety
drug DRUGBANK Nonoxynol-9
disease MESH asthma
pathway KEGG Asthma
disease MESH chronic bronchitis
disease MESH heart disease
disease MESH stroke
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH back pain
disease MESH arthrosis
disease MESH cancer
disease MESH neurological disorders

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *